197 related articles for article (PubMed ID: 36163264)
1. Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.
Bührer ED; Amrein MA; Forster S; Isringhausen S; Schürch CM; Bhate SS; Brodie T; Zindel J; Stroka D; Sayed MA; Nombela-Arrieta C; Radpour R; Riether C; Ochsenbein AF
Leukemia; 2022 Nov; 36(11):2634-2646. PubMed ID: 36163264
[TBL] [Abstract][Full Text] [Related]
2. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Mojtahedi H; Yazdanpanah N; Rezaei N
Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of myeloid leukemias by the bone marrow microenvironment.
Krause DS; Fulzele K; Catic A; Sun CC; Dombkowski D; Hurley MP; Lezeau S; Attar E; Wu JY; Lin HY; Divieti-Pajevic P; Hasserjian RP; Schipani E; Van Etten RA; Scadden DT
Nat Med; 2013 Nov; 19(11):1513-7. PubMed ID: 24162813
[TBL] [Abstract][Full Text] [Related]
6. Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches.
Krenn PW; Koschmieder S; Fässler R
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24326-24335. PubMed ID: 32929022
[TBL] [Abstract][Full Text] [Related]
7. Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia.
Lefort S; Maguer-Satta V
Biochem Soc Trans; 2020 Apr; 48(2):411-418. PubMed ID: 32167132
[TBL] [Abstract][Full Text] [Related]
8. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
9. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
10. Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors.
Tanaka Y; Takeda R; Fukushima T; Mikami K; Tsuchiya S; Tamura M; Adachi K; Umemoto T; Asada S; Watanabe N; Morishita S; Imai M; Nagata M; Araki M; Takizawa H; Fukuyama T; Lamagna C; Masuda ES; Ito R; Goyama S; Komatsu N; Takaku T; Kitamura T
Nat Commun; 2022 Jan; 13(1):271. PubMed ID: 35022428
[TBL] [Abstract][Full Text] [Related]
11. CD150(-) Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1.
Wang Z; Chen CC; Chen W
Stem Cells; 2015 Dec; 33(12):3437-51. PubMed ID: 26466808
[TBL] [Abstract][Full Text] [Related]
12. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
13. Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Jin Y; Yao Y; Chen L; Zhu X; Jin B; Shen Y; Li J; Du X; Lu Y; Jiang S; Pan J
Theranostics; 2016; 6(11):1947-62. PubMed ID: 27570562
[TBL] [Abstract][Full Text] [Related]
14. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
[TBL] [Abstract][Full Text] [Related]
15. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Scott MT; Korfi K; Saffrey P; Hopcroft LE; Kinstrie R; Pellicano F; Guenther C; Gallipoli P; Cruz M; Dunn K; Jorgensen HG; Cassels JE; Hamilton A; Crossan A; Sinclair A; Holyoake TL; Vetrie D
Cancer Discov; 2016 Nov; 6(11):1248-1257. PubMed ID: 27630125
[TBL] [Abstract][Full Text] [Related]
17. Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Mukaida N; Tanabe Y; Baba T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829353
[TBL] [Abstract][Full Text] [Related]
18. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Cheloni G; Tanturli M; Tusa I; Ho DeSouza N; Shan Y; Gozzini A; Mazurier F; Rovida E; Li S; Dello Sbarba P
Blood; 2017 Aug; 130(5):655-665. PubMed ID: 28576876
[TBL] [Abstract][Full Text] [Related]
19. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
[No Abstract] [Full Text] [Related]
20. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
